ANDON HEALTH(SZ:002432)2020-04-28 16:00Financial Performance - The company's operating revenue for Q1 2020 was ¥301,807,160.47, representing a 99.37% increase compared to ¥151,378,308.04 in the same period last year[3]. - Net profit attributable to shareholders was ¥46,063,209.39, a significant turnaround from a loss of ¥35,317,618.39, marking a 230.43% increase[3]. - Basic earnings per share were ¥0.1064, compared to a loss of ¥0.0816 per share in the same period last year, reflecting a 230.39% improvement[3]. - The company reported a net loss of CNY 61,521,498.50, an improvement from a loss of CNY 107,584,707.89 in the previous year[21]. - The net profit for Q1 2020 was CNY 49,163,869.82, a turnaround from a net loss of CNY 39,516,282.83 in the same quarter of the previous year[26]. - The total comprehensive income for the current period was ¥40,711,974.91, compared to a loss of ¥38,727,234.93 in the previous period[30]. Cash Flow - The net cash flow from operating activities reached ¥57,534,224.65, up 252.05% from a negative cash flow of ¥37,838,483.42 in the previous year[3]. - Cash flow from operating activities generated a net inflow of ¥57,534,224.65, contrasting with a net outflow of ¥37,838,483.42 in the previous period[32]. - The net cash flow from operating activities for the current period is ¥108,488,145.92, a significant improvement compared to the previous period's net cash flow of -¥54,146,831.62[34]. - Cash inflow from operating activities totaled ¥264,243,994.77, up from ¥71,525,333.15 in the previous period, indicating a growth of approximately 269%[34]. - The total cash outflow from operating activities increased to ¥155,755,848.85 from ¥125,672,164.77, representing a rise of about 24%[34]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,173,419,273.14, an increase of 11.53% from ¥1,948,728,136.08 at the end of the previous year[3]. - Current liabilities rose significantly to CNY 321,756,885.86, compared to CNY 162,368,740.66, marking an increase of about 97.8%[20]. - Non-current liabilities totaled CNY 209,004,539.05, up from CNY 201,485,405.69, reflecting a growth of approximately 3.8%[20]. - The company's total equity reached CNY 1,642,657,848.23, an increase from CNY 1,584,873,989.73, indicating a growth of about 3.6%[21]. - The total liabilities increased to CNY 530,761,424.91 from CNY 363,854,146.35, reflecting a growth of approximately 46.0%[20]. Shareholder Information - The company reported a total of 83,246 common shareholders at the end of the reporting period[6]. - The largest shareholder, Shihezi Sanhe Equity Investment Partnership, held 30.49% of the shares, amounting to 131,980,702 shares[6]. - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[7]. Research and Development - Research and development expenses increased by 69.72% to CNY 27,131,120.13 from CNY 15,985,441.89, reflecting higher investments in internet and medical business[9]. - Research and development expenses for Q1 2020 were CNY 27,131,120.13, up from CNY 15,985,441.89, reflecting an increase of 69.5% year-over-year[25]. - Research and development expenses for the current period were ¥10,736,092.64, slightly up from ¥10,365,297.98 in the previous period[28]. Investment and Income - Investment income skyrocketed by 82,826.40% to CNY 335,655,323.89 from CNY 404,762.95, due to distributions from invested funds[10]. - The company reported a significant increase in cash received from sales, totaling CNY 359,786,465.32, a 94.06% rise from CNY 185,400,822.32, driven by sales growth[10]. - The company’s deferred income increased by 375.61%, reflecting government subsidies received related to assets[9]. Financial Expenses - The company's financial expenses decreased by 130.02% to -CNY 5,984,744.51 from CNY 19,934,099.27, mainly due to foreign exchange gains[9]. - The company recorded a decrease in financial expenses, with interest expenses at ¥2,894,412.29, down from ¥13,500,314.88 in the previous period[28].